Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 211

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 211
---

     
    $
    40,876

    $
    37,706

    $
    3,170

    Marketable securities – current

    128,578

    165,351

    (36,773
    )

    Marketable securities – noncurrent

    13,843

    25,505

    (11,662
    )

    Total financial assets
     
    $
    183,297

    $
    228,562

    $
    (45,265
    )

    Working capital:

    Current assets
     
    $
    175,658

    $
    207,409

    $
    (31,751
    )

    Current liabilities

    14,370

    14,029

    341

    Total working capital
     
    $
    161,288

    $
    193,380

    $
    (32,092
    )

 95

Sources of Liquidity

Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. As of December 31, 2024, we had cash, cash equivalents, and marketable securities of $183.3 million and an accumulated deficit of $368.7 million. We have financed our operations primarily through issuance and sales of our equity securities.

On November 20, 2024 we filed a shelf registration statement on Form S-3 (File No. 333-283349) with the SEC and a prospectus supplement, which registered the offering, issuance and sale of up to $200,000,000 of various equity and debt securities and up to $113.8 million of common stock pursuant to an at-the-market equity offering program with Jefferies LLC, dated October 4, 2021, or the ATM Program. The SEC declared the registration statement effective on November 27, 2024. During the year ending December 31, 2024, we did not sell any shares of our common stock pursuant to the ATM Program. As of December 31, 2024, we had approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

Contractual Oblig